Navigation Links
BBK Worldwide Celebrates 25th Anniversary of Industry Leadership Through Innovation in Patient Enrollment
Date:6/25/2008

Pioneering firm marks milestone with initiatives aimed at knowledge

transfer, including landmark medical research collaboration between

Massachusetts and the Italian government in Lombardia

NEWTON, Mass., June 25 /PRNewswire/ -- BBK Worldwide, an innovator and leader in global patient recruitment for clinical trials, marks its 25th anniversary this year with a variety of initiatives to make its quarter-century of expertise more accessible to and beneficial for the life-sciences industry.

These efforts include a recent groundbreaking knowledge and technology transfer agreement between the Commonwealth of Massachusetts and the Lombardia region of Italy, and follow the recent release of BBK's comprehensive industry guidebook, Reinventing Patient Recruitment: Revolutionary Ideas for Clinical Trial Success, authored by the firm's co-founders, Bonnie A. Brescia, president, and Joan F. Bachenheimer, CEO and director of creative strategies.

"Just as business incubators accelerate the successful development of entrepreneurial companies through an array of support services, our aim has always been -- and continues to be -- to accelerate the patient enrollment process, helping sponsors conduct appropriate research with as many patients as possible," Brescia said.

"Since BBK opened its doors in July 1983, we've amassed a considerable body of knowledge regarding successful patient enrollment in clinical trials," Bachenheimer added. "We believe that transfer of this knowledge can contribute to enhancing the drug development process and reducing cycle time, which ultimately gets new medications to doctors and patients as expeditiously as possible."

BBK's current efforts include participation in the Clinical Research Consortium of Massachusetts (CRCM), a group of four organizations selected by the Massachusetts Office of International Trade and Investment to help Italy's Lombardia region attract more clinical studies and
'/>"/>

SOURCE BBK Worldwide
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
2. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
7. Getty Images Celebrates Conclusion of Change Me Imagery Forum
8. Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years
9. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
10. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, Inc. ... results from the  IAP310 study have been published ... a peer-reviewed journal with broad, multidisciplinary readership. ... evaluating the safety and efficacy of Zalviso, also ... (SSTS), for the treatment of post-operative pain in ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( www.pneumrx.com ... today announced completion of enrollment in their RENEW Study, ... Study is the FDA-approved IDE pivotal trial for the ... It was anticipated that the study, which ... would take until the end of 2014 to enroll ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company ... on the early diagnosis and preventive treatment of cardiometabolic ... selected by Windhover as one of the "Top Biopharma ... This announcement is part of the conference event organized ...
... Pasteur, the vaccines division of the sanofi-aventis Group ... announced today the results of the Phase III ... Virus Vaccine) candidate compared to Fluzone (Influenza Virus ...  Data from the clinical trial assessing the immunogenicity ...
Cached Medicine Technology:GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 3Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 2Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 3Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 4Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 5
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... global pharmaceutical giant Novartis bagged the contract to make ... vaccines. The $54.8 million contract// was finalised on Wednesday. ... million in federal contracts to fight a possible bird-flu ... also awarded contracts on Wednesday by the U.S. Department ...
... participate in a five-year study, to evaluate the risks of ... . ,Professor Lawrie Challis, an authority on mobile ... the Department of Health and the mobile phone industry. If ... of the study, which is expected to cost ?3 million. ...
... corporate downsizing not only affects those who lose jobs ... ,'Employees who remained in work after downsizing may ... said lead author Mika Kivimaki, from the Department of ... ,'In other words, enforced redundancies may boost mental ...
... failure, says a new study. // ,Gregg Fonarow ... of over 100,000 patients hospitalised because their heart condition was ... ,They found that the fatter the person, the less likely ... researchers reported their findings in the latest issue of the ...
... world were infected by HIV in each day of the year ... total, around 410,000 to 660,000 children under the age of 15 ... ,The report added that most of the children were infected ... half of the children infected last year would die of AIDS-related ...
... are becoming an increasingly important method for detecting malaria. ... a range of other strategies for controlling the disease ... insecticide-treated bed nets, indoor spraying against malaria-carrying mosquitoes and ... ,The tests are ideal for rural areas ...
Cached Medicine News:Health News:Downsizing Affects All Workers 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
... Volk's super ... biomicroscopy lenses. Examination ... Provide unprecedented fundus ... addressing maximum potential ...
... series slit lamp biomicroscopy ... of the posterior pole. ... capability, specifically addressing maximum ... fundus image resolution & ...
Volk indirect lenses. High magnification views of the posterior pole....
Medicine Products: